KCNJ11 and Hypoglycemia: The P.R.R. for pancreatic cancers of glipizide, gliclazide, and nateglinide appears to be inversely correlated with their IC50 to block the recombinant Kir6.2-Sur1 subunits with the glipizide, gliclazide, and nateglinide showing the highest cancer risk and the lowest hypoglycemia risk (Figure 6) within the KATP channel blockers including zoledronic acid.